Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 62.4%

Neg 62.4% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.